aTYR PHARMA (ATYR) Cash from Investing Activities (2014 - 2026)

aTYR PHARMA (ATYR) has reported Cash from Investing Activities for 13 consecutive years, with $15.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Investing Activities rose 364.16% year-over-year to $15.3 million; the trailing twelve-month figure through Jun 2026 stood at $22.9 million (up 113.01% YoY), and the FY2025 full-year result was -$5.1 million, down 129.32% from the prior year.
• Cash from Investing Activities improved to $15.3 million in Q2 2026 per ATYR's latest filing, from $11.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $20.6 million in Q3 2022 and bottomed at -$38.2 million in Q1 2023.
• Historically, Cash from Investing Activities has averaged $3.7 million across 5 years, with a median of $5.6 million in 2023.
• The widest YoY moves for Cash from Investing Activities: up 791.35% in 2023, down 360.99% in 2023.
• Over 5 years, Cash from Investing Activities stood at $2.0 million in 2022, then surged by 791.35% to $17.8 million in 2023, then slumped by 134.15% to -$6.1 million in 2024, then surged by 370.22% to $16.4 million in 2025, then slipped by 6.82% to $15.3 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $15.3 million, $11.5 million, and $16.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.